Risk factors for arterial hypertension after liver transplantation

Stefano, Cristina Di; Vanni, Ester; Mirabella, S.; Younes, Ramy; Boano, Valentina; Mosso, Elena; Nada, E.; Milazzo, Valeria; Maule, Simona; Romagnoli, Renato; Salizzoni, Mauro; Veglio, Franco; Milan, Alberto

doi:10.1016/j.jash.2018.01.002

Cited by 14 publications

(11 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there are data that correlate mTOR (mammalian target of rapamycin inhibitors) with systemic arterial hypertension, this was not observed in our study, since the number of patients who used this drug was very small (Di Stefano C et al (7) ).…”

Section: Discussionmentioning

confidence: 54%

“…Systemic arterial hypertension (SAH) manifested after liver transplantation is associated with the use of isolated or associated immunosuppressants, such as calcineurin inhibitors (cyclosporine and tacrolimus), corticosteroids, mTOR (mammalian target of rapamycin inhibitors), in addition to other factors such as alteration of renal function and steatosis (6,7) . Calcineurin inhibitors cause widespread arterial vasoconstriction and this promotes sodium re-absorption and, consequently, higher volume of water, which results in increased volemia and thus leads to increased blood pressure (8) Thereby, systemic arterial hypertension is a complication in liver transplants recipients and can have severe influences on quality of life and even on morbidity and mortality of individuals (6,8) .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and Time of Development of Systemic Arterial Hypertension in Patients After Liver Transplantation

Lemos

Silva

2021

Arq. Gastroenterol.

View full text Add to dashboard Cite

BACKGROUND: The use of immunosuppressive drugs after liver transplantation (LT) is associated with the development of systemic arterial hypertension (SAH), in addition to other comorbidities of metabolic syndrome. OBJECTIVE: Therefore, the purpose of this study was to analyze the time after use immunosuppressive drugs the patient progresses to SAH, as well as to identify its prevalence and the factors that may be correlated to it. METHODS: A retrospective and longitudinal study was conducted, based on the analysis of medical records of 72 normotensive patients, attended in the transplant unit of a university hospital, between 2016 and 2019. RESULTS: It was observed, on average, 9±6.98 months after immunosuppressive use, the patients were diagnosed with hypertension, and the prevalence of transplanted patients who evolved to SAH in this study was 59.64% (41 patients). In addition, there was a correlation between serum dosage of tacrolimus and the development of SAH (P=0.0067), which shows that tacrolimus has a significant role in the development of SAH. Finally, it was noticed that the development of post-transplantation hypertension indicates a higher risk of the patient presenting the other parameters of metabolic syndrome, as well as a higher impairment in its renal function (P=0.0061). CONCLUSION: This study shows that the patients evolved to SAH in an average of 9±6.98 months after immunosuppressive drug use. We have also found high prevalence of systemic arterial hypertension (59.64%) in patients after liver transplantation, who used calcineurin inhibitors, especially when associated with the use of tacrolimus.

show abstract

Section: Discussionmentioning

confidence: 54%

Section: Introductionmentioning

confidence: 99%

Prevalence and Time of Development of Systemic Arterial Hypertension in Patients After Liver Transplantation

Lemos

Silva

2021

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…The difference between the prevalence of hypertension worldwide is attributed to the changes in factors such as age, BP measurement and analysis methods, obesity, ethnic origin, environmental factors, the drugs used and co-morbid diseases [11]. In studies conducted with adult liver transplant patient groups with different characteristics and numbers, the prevalence of arterial hypertension varying between 50% and 90% has been reported [2,12,15]. In the studies conducted with pediatric liver transplant recipients, Bayrakçı et al [7] reported hypertension as 30%, and Del Compare et al [8] as 27%.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of arterial hypertension by ambulatory blood pressure monitoring in pediatric liver transplant recipients

Arikanoğlu¹,

Tabel

Selimoğlu³

2021

Blood Pressure Monitoring

View full text Add to dashboard Cite

Objective Many cardiovascular complications, including hypertension, are seen in pediatric liver transplantation. The purpose of this study was to analyze the frequency of arterial hypertension of pediatric liver transplant recipients and also to determine the related risk factors.Methods Thirty-six pediatric liver transplant recipients aged 8-17 years were prospectively studied by manual and ambulatory blood pressure measurement (ABPM) technique. ResultsThe mean age of patients was 12.42 ± 2.74 years and the mean ABPM measurement time after transplantation was 2 years (3 months-5.9 years). Only one (2.7%) patient was detected as hypertensive by casual measurement, but 17 (47.2%) patients were found to be hypertensive when measured through ABPM. Of children that were found to be hypertensive as a result of ABPM, 64.7% were observed to have a nondipper pattern. Considering the time passed after the transplantation, patients were found to be more hypertensive in the first 2 years posttransplant although it was not found statistically significant. ConclusionsIn this study, it has been shown that it is possible to diagnose hypertension at an earlier period of transplantation using ABPM in pediatric liver transplant patients. ABPM is needed to detect masked hypertension that may develop following liver transplantation. Blood

show abstract

“…An increased incidence of hypertension has been described in many studies. The incidence of post-transplant hypertension ranged in different studies from 19% to 77% at 1-year post-transplant [10][11][12][13][14][15][16][17][18] .…”

Section: Discussionmentioning

confidence: 99%

Incidence and Risk Factors for Diabetes, Hypertension and Hyperlipidemia after Liver Transplantation

Hashim¹,

Alsabaawy²,

Afify³

et al. 2020

Journal of Gastroenterology and Hepatology Research

View full text Add to dashboard Cite

show abstract

Risk factors for arterial hypertension after liver transplantation

Cited by 14 publications

References 40 publications

Prevalence and Time of Development of Systemic Arterial Hypertension in Patients After Liver Transplantation

Prevalence and Time of Development of Systemic Arterial Hypertension in Patients After Liver Transplantation

Evaluation of arterial hypertension by ambulatory blood pressure monitoring in pediatric liver transplant recipients

Incidence and Risk Factors for Diabetes, Hypertension and Hyperlipidemia after Liver Transplantation

Contact Info

Product

Resources

About